Citadel Advisors’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
Sell
-42,956
Closed -$2.06M 10945
2020
Q1
$2.06M Sell
42,956
-749,915
-95% -$34.9M ﹤0.01% 4097
2019
Q4
$37.2M Buy
792,871
+681,925
+615% +$30.1M 0.02% 976
2019
Q3
$2.62M Buy
+110,946
New +$3.29M ﹤0.01% 4054
2019
Q2
Sell
-339,544
Closed -$7.78M 10216
2019
Q1
$7.61M Sell
339,544
-748,926
-69% -$16.1M ﹤0.01% 2406
2018
Q4
$19.8M Buy
1,088,470
+759,445
+231% +$11.9M 0.01% 1248
2018
Q3
$5.95M Sell
329,025
-20,176
-6% -$239K ﹤0.01% 2765
2018
Q2
$3.48M Buy
349,201
+18,754
+6% +$129K ﹤0.01% 3279
2018
Q1
$1.75M Buy
330,447
+30,980
+10% +$221K ﹤0.01% 3940
2017
Q4
$2.54M Sell
299,467
-19,947
-6% -$245K ﹤0.01% 3303
2017
Q3
$4.66M Buy
+319,414
New +$4.83M ﹤0.01% 2374

Other funds holding RARX

Citadel Advisors's RARX Position: Q2 2020 in Review

Citadel Advisors sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 42,956 shares — an estimated $2.06M sold.

Citadel Advisors first reported a position in RARX in Q3 2017 and held it in 10 quarters. The position peaked at $37.2M in Q4 2019. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

  • Citadel Advisors reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Citadel Advisors sold 42,956 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $2.06M.
  • Citadel Advisors first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 10 quarters.
  • Citadel Advisors's Ra Pharmaceuticals, Inc. Common Stock position peaked at $37.2M in Q4 2019.
  • 1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Citadel Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.